This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Meningococcal polysaccharide a, c, w135, y conjugate vaccine

Updated 2 Feb 2023 | Meningococcal vaccine


Pre-filled syringe
One dose (0.5ml of reconstituted vaccine) contains:

Meningococcal group A polysaccharide 5micrograms
Meningococcal group C polysaccharide 5micrograms
Meningococcal group W135 polysaccharide 5micrograms
Meningococcal group Y polysaccharide 5micrograms

Conjugated to tetanus toxoid carrier protein.

One dose (0.5ml of reconstituted vaccine) contains:

Meningococcal group A polysaccharide 10micrograms
Meningococcal group C polysaccharide 10micrograms
Meningococcal group W135 polysaccharide 10micrograms
Meningococcal group Y polysaccharide 10micrograms

Conjugated to tetanus toxoid carrier protein.

Drugs List

  • meningococcal polysaccharides a c w135 and y conjugate vaccine pre-filled syringe
  • meningococcal polysaccharides a c w135 and y conjugate vaccine vial
  • MENQUADFI vaccine
  • NIMENRIX vaccine
  • Therapeutic Indications


    Prophylaxis against meningococcal meningitis group A, C, W135 and Y

    Active immunisation of individuals at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.



    Single dose of 0.5ml.


    Pre-filled syringe
    Children aged from 6 weeks to 6 months
    Two doses of 0.5ml, with an interval of 2 months between doses.

    Children aged 6 months to 18 years
    Single dose of 0.5ml.

    Children aged 12 months to 18 years
    Single dose of 0.5ml.

    Additional Dosage Information

    If a toddler is at a particular risk of invasive meningococcal disease after exposure to Neisseria meningitidis groups W-135 or Y, consider administering a second vaccine dose after an interval of two months. The vaccine-elicited bactericidal response against groups W-135 and Y is higher after two doses compared to one.
    A booster dose may be considered in individuals vaccinated at toddler age who remain exposed to meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 or Y.


    To be given by intramuscular injection into the deltoid. Individuals under 1 year of age may be administered into the anterolateral aspect of the thigh.


    Children under 6 weeks
    Severe febrile conditions

    Precautions and Warnings

    Children aged 6 weeks to 12 months
    Hereditary complement deficiencies
    Immunodeficiency syndromes

    Postpone immunisation if there is active or suspected infection
    Advise ability to drive/operate machinery may be affected by side effects
    Impaired response possible in immunocompromised patients
    Not all available brands are licensed for all age groups
    Protection against meningococci groups A, C, W135 and Y only
    Vaccine may not be effective in 100% of patients
    Do not mix with other vaccines in the same syringe
    Do not use if solution is discoloured or particulates are apparent
    Inject other vaccines at different sites
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Establish full medical history and health status prior to vaccine
    Remain alert to possible coincidental meningitis
    Follow national immunisation guidelines

    Syncope can occur before or following vaccination, especially in adolescents as a psychogenic response to the needle injection. Ensure procedures are in place to avoid injury from faints.

    The vaccine should administered at least one month before an anti-tetanus toxoid containing vaccine, or co-administered at the same time.

    Lower hSBA geometric mean titres (GMTs) against serogroup A have been observed following a single dose of the vaccine. This should be considered for individuals at high risk of MenA infection who received MenC-CRM vaccine in their first year of life.

    Pregnancy and Lactation


    Use meningococcal A, C, W135 and Y conjugate vaccine with caution during pregnancy.

    The manufacturer advises meningococcal vaccines may be used during pregnancy if the expected benefits outweigh the potential risks. At the time of writing there is limited published information regarding the use of meningococcal vaccines during pregnancy. Potential risks are unknown.


    Use meningococcal A, C, W135 and Y conjugate vaccine with caution during breastfeeding.

    The manufacturer advises meningococcal vaccines may be used when breastfeeding if the advantages outweigh the potential risks. The presence of meningococcal vaccines in human breast milk and its effect on exposed infants is unknown.

    Side Effects

    Abdominal pain
    Axillary pain
    Decreased appetite
    Erythema at injection site
    Gastro-intestinal symptoms
    Haematoma (injection site)
    Induration (injection site)
    Limb swelling
    Local pain (injection site)
    Localised areas of anaesthesia
    Painful extremities
    Sensation of warm and/or cold at injection site
    Swelling (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2021

    Reference Sources

    Summary of Product Characteristics: MenQuadfi solution for injection. Sanofi Pasteur. Revised September 2021.

    Summary of Product Characteristics: Nimenrix powder and solvent for solution for injection in pre-filled syringe. Pfizer Limited. Revised October 2021.

    Immunisation against infectious diseases: 'The Green Book', Department of Health.
    Available at:
    Last accessed: 13 October 2021

    NICE Evidence Services
    Available at:
    Last accessed: 13 October 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.